Strategic Transformation in Pharma: The Driving Forces Behind Innovation from Policy to Commercialization

In recent years, driven by the triple forces of technological advancements, capital infusion, and policy support, China’s innovative drug industry has entered a new cycle of rapid development. New technologies such as small-molecule targeted therapies, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), cell therapies, PROTACs, and nucleic acid drugs are increasingly maturing, with a growing number of products advancing to the commercialization stage, including many with blockbusters potential.

For innovative pharmaceutical companies, in addition to intensifying R&D innovation and continuing to climb up the high end of the value chain, the key to accelerating the implementation of innovations and driving commercial success of their products lies in how they combine product characteristics with commercialization strategies that align with their own resource endowments.

To this end, market players in different ecological niches have leveraged their respective strengths. Big Pharma, with its strong commercialization capabilities, chooses to further enrich and refine its product pipeline through license-in arrangements to save R&D time and costs. Biopharma companies, which maintain multiple pipelines, continue to consolidate their competitive advantages through both license-in and license-out strategies. Driven by R&D, Biotech firms primarily generate revenue through license-out deals, laying the foundation for their subsequent transformation into Biopharma entities.

In this context, the strength of business development (BD) capabilities has become increasingly critical to the future growth of pharmaceutical companies. Gaining an in-depth understanding of BD trends within the industry and integrating them with a company’s own needs is not only a logical imperative but also essential for survival and development.

In this session, DXY Insight Online Lecture Hall, in collaboration with VBInsight New Medicine, specially invites Mr. Wang Yong, VP of Business Development at CMS Biotech and Investment Director at China Medical System (CMS) Hong Kong Venture Capital, to present on the theme “How Large Pharmaceutical Companies Can Achieve Transformation and Innovation Through Business Development in the New Landscape.” He will outline the new changes and trends in business development within the industry, helping you build core competencies based on BD.

Course Topic: How Large Pharmaceutical Companies Can Achieve Transformation and Innovation Through Business Development in the New Landscape

Course Guest: Wang Yong, VP of Business Development at CMS Biotech Pte. Ltd. (CMS Group’s Southeast Asia subsidiary) and Investment Director at CMS Hong Kong Venture Capital

Bachelor’s degree from China Pharmaceutical University; MBA from The University of Hong Kong. Over 20 years of experience in the pharmaceutical industry, with 12 years of specialized expertise in Business Development (BD). Previously held positions at the Southern Institute of Pharmaceutical Economics, Nielsen, UCB, GSK, Sumitomo Pharma, and biotech startups, boasting a comprehensive career spanning state-owned enterprises, multinational corporations, and biotech firms, along with extensive BD experience. Successfully executed over 20 BD projects, including in/out-licensing deals (e.g., Zyrtec, New Contac, Lisheng, and Lefamulin), establishment of joint ventures, and mergers and acquisitions. Possesses in-depth knowledge of both prescription drugs and OTC products. Additionally, excels in market research, having moderated more than 50 focus group discussions.

Course Duration: Tuesday, April 19, 2022, 10:00–11:00

Course Highlights：

1. What new changes have emerged in the business development (BD) divisions of multinational pharmaceutical companies?

2. What are the strategic adjustments in BD approaches for domestic giants?

3. What are the diverse options for biotech companies expanding globally?

Registration Method: Scan the QR code below to register for free.

Scan the QR code to join the group and chat with more pharmaceutical peers about various topics:

Insight Database is a data intelligence platform established by DXY in the pharmaceutical field. It encompasses comprehensive lifecycle data for domestic and international drugs, including regulatory submission progress, clinical trials, marketed products, generic consistency evaluations, and market access. The platform also features unique integrated analysis modules such as drug candidate screening, corporate analysis, global new drug tracking, and clinical trial results. Accessible via PC and WeChat Mini Program, Insight Database is committed to providing efficient, convenient, and feature-rich data intelligence query services to participants in the pharmaceutical industry.

VB BioPharma is a media and research platform under VCBeat, focusing on the biopharmaceutical sector. It empowers innovators and entrepreneurs to communicate their value through two key dimensions: content and operations. In terms of content, it primarily features corporate profiles of companies in cutting-edge fields, investment and financing updates, R&D progress, reviews of outstanding domestic and international case studies, and industry reports on specialized segments. On the operational front, through its branded column “VB Think Tank,” it focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through the exchange of ideas. Featured series include: [IPOs in Progress], [Financial Report Analysis], [iPSC], [Radiopharmaceuticals], [Small-Molecule Degraders], and [Upstream Tools].